We are live on ! Find out more
MBOT icon

Microbot Medical

1.15 USD
+0.06
5.5%
At close Updated Nov 4, 9:43 AM EST
1 day
5.5%
5 days
5.5%
1 month
7.48%
3 months
-36.81%
6 months
-45.5%
Year to date
-45.5%
1 year
-43.07%
5 years
-84.4%
10 years
-98.92%
 

About: Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.

Employees: 22

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
8 days ago
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company's Full Market Release strategy.  The Company believes the OBLs represent a rapidly growing healthcare segment and opportunity as many endovascular procedures are being done outside traditional hospital settings and Ambulatory Surgery Centers.
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
Neutral
GlobeNewsWire
12 days ago
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
HINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that key executives and members of the Company's commercial team will be attending the SIR EDGE 2026 conference in Louisville, Kentucky, providing an opportunity for the Company to engage with prospective customers.
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
Neutral
GlobeNewsWire
15 days ago
Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio
The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.
Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio
Neutral
GlobeNewsWire
29 days ago
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S. HINGHAM, Mass.
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Neutral
GlobeNewsWire
1 month ago
Microbot Medical® Highlights Growth Strategy
Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
Microbot Medical® Highlights Growth Strategy
Neutral
Zacks Investment Research
2 months ago
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites of service HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission (SEC).
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Positive
Zacks Investment Research
3 months ago
New Strong Buy Stocks for July 23rd
PLGO, BLPD, INN, RFIL and MBOT have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2026.
New Strong Buy Stocks for July 23rd
Neutral
GlobeNewsWire
3 months ago
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year's Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL.
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
Neutral
GlobeNewsWire
4 months ago
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026.
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Price charts implemented using Lightweight Charts™